For a newly diagnosed hypertensive adult with no comorbidities, which first‑line antihypertensive medication should be started?

First-Line Antihypertensive Medication for Newly Diagnosed Hypertension

Start with a thiazide-like diuretic—specifically chlorthalidone 12.5–25 mg once daily—as the optimal first-line agent for most newly diagnosed hypertensive adults without comorbidities, based on the strongest cardiovascular outcome evidence from the ALLHAT trial of over 50,000 participants. 1

Blood Pressure Classification and Treatment Threshold

• Confirm the diagnosis with out-of-office monitoring (home BP ≥135/85 mmHg or 24-hour ambulatory BP ≥130/80 mmHg) to exclude white-coat hypertension before starting medication. 1
• Stage 1 hypertension (130–139/80–89 mmHg): Begin pharmacologic therapy only if the patient has established cardiovascular disease or a 10-year ASCVD risk ≥10% calculated with the ACC/AHA Pooled Cohort Equations; otherwise, start with intensive lifestyle modification for 3 months. 1
• Stage 2 hypertension (≥140/90 mmHg): Initiate medication immediately alongside lifestyle measures—do not delay beyond 3 months. 1

Recommended First-Line Agent: Chlorthalidone

Chlorthalidone is superior to all other first-line classes for cardiovascular outcomes in the general adult population without compelling indications. 1

• In the ALLHAT trial, chlorthalidone reduced heart failure incidence by 38% compared with amlodipine and stroke incidence by 15% compared with lisinopril. 1
• Chlorthalidone provides 24-hour blood pressure control due to its 40–60 hour half-life and large volume of distribution. 1
• Starting dose: 12.5 mg once daily to minimize metabolic side effects (hypokalemia, hyperglycemia). 1
• Titration: Increase to 25 mg once daily after 4 weeks if BP remains ≥130/80 mmHg; doses >25 mg increase adverse effects without additional benefit. 1

Alternative First-Line Agents (When Thiazides Are Contraindicated or Not Tolerated)

• Long-acting dihydropyridine calcium channel blockers (e.g., amlodipine 5–10 mg daily) achieve cardiovascular event reduction comparable to chlorthalidone for all outcomes except heart failure, where thiazides remain superior. 1
• ACE inhibitors (e.g., lisinopril 10–40 mg daily) or ARBs (e.g., losartan 50–100 mg daily) are reasonable alternatives but were 15% less effective for stroke prevention and 19% less effective for heart failure prevention than chlorthalidone in ALLHAT. 1

Monotherapy vs. Combination Strategy

• Stage 1 hypertension: Start with single-agent monotherapy (chlorthalidone 12.5 mg) and titrate upward before adding a second agent from a different class. 1
• Stage 2 hypertension: Begin with a two-drug combination from different first-line classes (e.g., chlorthalidone + ACE inhibitor/ARB or amlodipine + ACE inhibitor/ARB), preferably as a single-pill formulation to improve adherence. 1
• Combination therapy using two submaximal doses from different classes yields larger BP reductions with fewer adverse effects than maximal dosing of a single agent. 1

Blood Pressure Target

• Aim for BP <130/80 mmHg in all adults with hypertension, irrespective of age or comorbidities. 1
• For community-dwelling adults ≥65 years, a systolic target <130 mmHg is recommended if tolerated. 1

Baseline Laboratory Evaluation and Monitoring

• Before starting medication: Obtain serum creatinine, estimated glomerular filtration rate (eGFR), potassium, sodium, fasting glucose, and uric acid. 1
• After initiating chlorthalidone: Repeat labs 1–2 weeks after starting to detect hyponatremia, hypokalemia, and changes in renal function; also monitor uric acid, especially in patients with a history of gout. 1
• Follow-up visits: Schedule monthly until BP target is achieved, then every 3–5 months for maintenance. 1

Agents to Avoid as First-Line Therapy

• Beta-blockers should not be used for uncomplicated hypertension, especially in patients >60 years, because they are ≈36% less effective than calcium channel blockers and ≈30% less effective than thiazides for stroke prevention. 1
• Alpha-blockers (e.g., doxazosin) are not first-line; in ALLHAT they were associated with an 80% higher rate of heart failure compared with chlorthalidone. 1
• Hydrochlorothiazide doses <25 mg daily as monotherapy are discouraged because such low doses are unproven or less effective in outcome trials. 1
• Clonidine should never be used as initial therapy due to significant CNS adverse effects, especially in older adults, and risk of rebound hypertension. 2

Common Pitfalls to Avoid

• Delaying combination therapy in Stage 2 hypertension (i.e., starting with monotherapy when BP ≥140/90 mmHg) increases cardiovascular risk. 1
• Relying on a single office measurement without out-of-office confirmation can lead to over-diagnosis; improper technique can falsely raise readings by 10–30 mmHg. 1
• Combining an ACE inhibitor with an ARB (or adding a direct renin inhibitor) is contraindicated because it raises the risk of hyperkalemia and acute kidney injury without added cardiovascular benefit. 1
• Failing to employ out-of-office blood pressure monitoring can miss white-coat or masked hypertension, compromising management. 1